Marina
Rodrigues
*a,
Caroline
Bertoncini-Silva
a,
Anderson Gregorio
Joaquim
a,
Cássia Dias
Machado
a,
Leandra Náira Zambelli
Ramalho
b,
Daniela
Carlos
c,
Priscila Giacomo
Fassini
a and
Vivian Marques Miguel
Suen
a
aDepartment of Internal Medicine, Division of Nutrology, Ribeirão Preto Medical School, University of São Paulo, Avenida Bandeirantes, 3900, Monte Alegre, CEP, 14049-900, Ribeirão Preto, São Paulo, Brazil. E-mail: marina.rnutri@gmail.com
bDepartament of Pathology, Ribeirão Preto Medical School, University of São Paulo, Avenida Bandeirantes, 3900, Monte Alegre, CEP, 14049-900, Ribeirão Preto, São Paulo, Brazil
cDepartment of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Avenida Bandeirantes, 3900, Monte Alegre, CEP, 14049-900, Ribeirão Preto, São Paulo, Brazil
First published on 17th February 2022
Due to the increase in the prevalence of obesity, new therapies have emerged and eugenol has been shown to be beneficial in metabolic changes and gut microbiota. This study aimed to investigate the effects of eugenol on gut microbiota, hepatic lipid accumulation, body weight, adipose tissue weight, lipid and glycemic profile in mice fed a high-fat diet. Forty C57BL/6 male mice were divided into standard diet (SD), high-fat diet (HFD), standard diet with eugenol (SDE) and high-fat diet with eugenol (HFDE). The dose used of eugenol was 500 mg kg−1 for 8 weeks. Eugenol did not prevent weight gain, but it was effective in preventing hepatic lipid accumulation evidenced by the presence of fat droplets in the HFD group and absence in the HFDE group. An improvement in the gut microbiota profile was observed, proved by an increase in the Actinobacteria phylum in the treated groups and a reduction of Proteobacteria phylum in the HFDE group. Despite not preventing weight gain, eugenol appeared to have a protective effect on hepatic lipid accumulation and beneficially modulate the gut microbiota in mice fed with HFD.
Recently, gut microbiota (GM) has been studied for playing an important role in the pathophysiology of obesity. Studies have shown a strong relationship between weight gain/obesity and the composition of the GM.10–13 The GM is composed mainly of seven phyla: Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Verrucomicrobia, Fusobacteria, and Cyanobacteria, with Firmicutes and Bacteroidetes being the most abundant species.10 The imbalance between beneficial and pathogenic bacteria that compose the microbiota is defined as dysbiosis.11,14 Lifestyle, diet, immune system, some types of antibiotics, age, and type of delivery are some factors that affect the GM and may contribute to dysbiosis and consequently to the development of many diseases.15–17 Studies have shown that the composition of the GM between healthy individuals and individuals with obesity is different, both in humans and in animal models.18,19 For example, individuals with obesity have an altered relationship between Bacteroidetes and Firmicutes, characterized by a decrease in the Bacteroidetes phylum and an increase in the Firmicutes phylum, compared to eutrophic individuals.11,20
Among the various treatment possibilities for obesity, unconventional therapies can be mentioned. One of these therapies is herbal medicines, which can contribute to satiety and increase energy metabolism and consequently promote weight loss.21 Eugenol is the major bioactive component extracted from clove oil22,23 and has anti-inflammatory, antimicrobial, antibacterial, antioxidant, antiviral, anesthetic, antitumor, antidiabetic, antiseptic, and insecticide effects.23–25 Wlodarska et al.26 performed a study testing six phytonutrients, including eugenol, to evaluate the mechanism of action and the ability to alter the mucosal immune responses in the intestines of mice. They showed that all phytonutrients promoted changes in the expression of innate immune genes in the colon. However, just eugenol stimulated the production of the inner mucus layer, an important barrier for microbes, suggesting that eugenol acts to strengthen the mucous barrier, which protects against pathogens and invasive diseases.
Therefore, considering the possible effects of eugenol modulating properties of the innate immune system in mouse intestine, and the role of the GM in the pathophysiology of obesity, we explore the effects of eugenol on the modulation of the GM to investigate whether this substance influences the bacterial profile, and verify if any associated changes to GM could be beneficial towards the prevention or treatment of obesity. Thus, this study aimed to investigate the effects of eugenol on gut microbiota, histology of the liver, body and adipose tissue weight in mice fed a high-fat diet.
The animals were randomly separated into four groups of ten animals each: standard diet (SD), high-fat diet (HFD), standard diet with eugenol (SDE), and high-fat diet with eugenol (HFDE). All groups were fed with an industrialized diet (AIN 93G) and the HFD group received 40% of lipids. The nutritional composition and the ingredients of the standard diet and the high-fat diet are described in Table 1.
Macronutrients | Standard dietb | High-fat dietc |
---|---|---|
a Source: PragSoluções. b Standard diet (AIN 93G), contains the following nutritional composition: 397.5 g corn starch; 200 g casein; 132 g dextrinized starch; 100 g sucrose; 70 g soybean oil; 50 g microcrystalline cellulose; 35 g mineral mix; 10 g vitamin mix; 3 g L-cystine; 2.5 g choline bitartrate; 0.014 g BHT. c High-fat diet (AIN 93 HF 40%), contains the following nutritional composition: 273.7 g corn starch; 220 g casein; 100 g dextrinized starch; 100 g sucrose; 40 g soybean oil; 167 g lard; 50 g microcrystalline cellulose; 35 g mineral mix; 10 g vitamin mix; 1.8 g L-cystine; 2.5 g choline bitartrate; 0.014 g BHT. | ||
Carbohydrates | 639.5 g (64%) | 483.7 g (41.3%) |
Lipids | 70 g (15.8%) | 207 g (39.8%) |
Proteins | 203 g (20.3%) | 221.8 g (18.9%) |
Energy | 4000 kcal | 4685.2 kcal |
Eugenol (97–99% purity) was purchased from Sigma-Aldrich (Ref: E5504). Animals from the SDE and HFDE groups received 500 mg kg−1 of body weight per day of eugenol supplementation with soybean oil as a vehicle by gavage. Groups that did not receive supplementation (SD and HFD), received only soy oil by gavage.
The animals were kept in an adaptation period for 3 weeks (pre-treatment) and received supplementation for 8 weeks (treatment period) thus undergoing 11 weeks of the experiment. They were weighed before the beginning of the experiment and weekly thereafter using a digital scale with a maximum capacity of 15 kg (Filizola S.A., São Paulo, Brazil).
At the end of the experiment, the animals were euthanized by decapitation and blood samples were collected and promptly centrifuged at 3500 rpm, 4 °C for 15 min to obtain the serum, which was kept in a freezer at −70 °C for subsequent biochemical analysis. During the sacrifice, samples of hepatic tissue, pancreas, epididymal, retroperitoneal, and brown adipose tissue were collected and weighed. Liver fragments were separated and fixed in 10% buffered formalin for 48 h and embedded in paraffin for histological analysis. Stool samples were collected for gut microbiota analysis and stored in a freezer at −70 °C until the analysis.
Fecal DNA was obtained using the DNeasy® PowerSoil® kit (Qiagen, Hilden, Germany). Relative abundance of bacteria from the Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria phyla was determined using universal primers for the 16S rRNA gene (Eubacteria) or specific for the different phyla.
The primer sequences are described in Table 2.29 The differences (ΔCT) between the cycle threshold (CT) values of Eubacteria and specific bacterial groups were used to obtain normalized levels of each bacterial group (2 − ΔCT). The relative abundance of each bacterial group was obtained after normalization with the control groups.
Primer | Sequência |
---|---|
Forward primer (FP), reverse primer (RP). Source: ref. 29. | |
Actinobacteria | FP-TGTAGCGGTGGAATGCGC |
RP-AATTAAGCCACATGCTCCGCT | |
Bacteroidetes | FP-GTTTAATTCGATGATACGCGAG |
RP-TTAASCCGACACCTCACGG | |
Firmicutes | FP-ATGTGGTTTAATTCGAAGCA |
RP-AGCTGACGACAACCATGCAC | |
Proteobacteria | FP-CATGACGTTACCCGCAGAAGAAG |
RP-CTCTACGAGACTCAAGCTTGC | |
Eubacteria universal | FP-ACTCCTACGGGAGGCAGCAGT |
RP-ATTACCGCGGCTGCTGGC |
SD | HFD | SDE | HFDE | |
---|---|---|---|---|
Standard diet (SD), high-fat diet (HFD), standard diet with eugenol (SDE), and high-fat diet with eugenol (HFDE). *Different from SD, &different from SDE. All the groups were analyzed by one-way ANOVA followed by Tukey's test (p < 0.05). Data are represented as mean ± standard deviation, n = 10 per group. | ||||
Initial weight (g) | 20 ± 1.7 | 19.5 ± 1.2 | 19.7 ± 0.9 | 19 ± 0.8 |
Final weight (g) | 28.8 ± 1.8 | 28.4 ± 2.0 | 26.7 ± 1.5 | 28.8 ± 1.7& |
Weight gain (%) | 44.5 ± 9.4 | 45.9 ± 10.2 | 35.7 ± 7.2 | 51.9 ± 11.6& |
Food intake (g per week) | 2.39 ± 0.06 | 1.91 ± 0.07* | 2.27 ± 0.07 | 2.04 ± 0.11 |
SD | HFD | SDE | HFDE | |
---|---|---|---|---|
Standard diet (SD), high-fat diet (HFD), standard diet with eugenol (SDE), and high-fat diet with eugenol (HFDE).* Different from SD. All the groups were analyzed by one-way ANOVA followed by Tukey's test (p < 0.05). Data are represented as mean ± standard deviation, n = 10 per group. | ||||
Retroperitoneal adipose tissue (g) | 0.52 ± 0.27 | 0.99 ± 0.40* | 0.46 ± 0.22 | 0.74 ± 0.35 |
Epididymal adipose tissue (g) | 1.35 ± 0.63 | 2.36 ± 0.78* | 1.53 ± 0.47 | 2.24 ± 0.79 |
Brown adipose tissue (g) | 0.34 ± 0.06 | 0.32 ± 0.08 | 0.36 ± 0.09 | 0.33 ± 0.79 |
Liver (g) | 3.97 ± 0.80 | 3.58 ± 0.44 | 4.41 ± 0.08 | 4.13 ± 0.43 |
Pancreas (g) | 0.43 ± 0.09 | 0.34 ± 0.08 | 0.42 ± 0.11 | 0.41 ± 0.07 |
SD | HFD | SDE | HFDE | |
---|---|---|---|---|
Standard diet (SD), high-fat diet (HFD), standard diet with eugenol (SDE), and high-fat diet with eugenol (HFDE). *Different from SD, #different from HFD, &different from SDE. All the groups were analyzed by one-way ANOVA followed by Tukey's test (p < 0.05). Data are represented as mean ± standard deviation, n = 10 per group. | ||||
HDL cholesterol (mg dL−1) | 84.5 ± 26.8 | 77.6 ± 14.4 | 58.6 ± 30.5 | 101.5 ± 13.8& |
Total cholesterol (mg dL−1) | 121.8 ± 29.6 | 123 ± 27.0 | 144.1 ± 47.4 | 178.1 ± 28.5# |
Triglycerides (mg dL−1) | 90.4 ± 29.2 | 55.8 ± 7.2* | 81.3 ± 28.1 | 61.2 ± 15.8 |
Insulin (ng dL−1) | 0.7 ± 0.4 | 0.7 ± 0.3 | 0.8 ± 0.5 | 1.02 ± 0.3 |
A preliminary study was previously carried out to define the eugenol dose used in the present study. However, the chosen dose is within a non-toxic dose according to De Souza.30 Regarding food intake, we observed a difference between the SD and HFD groups. Our findings agreed with White et al.,31 and although not significantly, the SD and SDE groups had a higher total food intake. Another study using an aspirin ester with eugenol (AEE) in Wistar rats for 8 weeks found that the food intake of the HFD and HFD + AEE groups was significantly lower than the SD group, and no difference was observed between the HDF and HFD + AEE groups.32
The body weight results showed a difference between SDE and HFDE groups, where the HFDE group showed higher weight gain (40%). The SD and HFD groups gained equal weight, which explains, the effectiveness of the diet since the HFD group had a lower food intake and gained more weight. This fact is due to the higher energy density of the high-fat diet. Our results differed from Jung et al. and Ding et al., where clove supplementation associated with HFD promoted less body weight gain when compared to HFD only.33,34 In this context, Harb et al. used two different doses of eugenol (10 mg and 100 mg per kg of body weight) in Wistar rats fed a hypercholesterolemic diet (HCD) and standard diet (SD) for 4 weeks. In contrast to the current study, all groups started the experiment with similar body weight, but animals from HCD and HCD + eugenol 100 mg groups gained less weight when compared to those of the SD group.35
After analyzing the tissue weight, no differences were found for the liver weight. Our findings diverge from previous studies, since Jung et al. and Ding et al. observed lower liver weight for the high-fat diet treated group compared to the untreated group.33,34 Another study supplemented eugenol in C57BL/6J mice fed HFD for 12 weeks and found that eugenol significantly reduced liver weight compared to the untreated HFD group.36 These controversial results can be explained by the time of treatment of our study, which was shorter than of other studies. Later, Harb et al. concluded that the groups fed with HCD and HCD + eugenol (10 mg and 100 mg) had a higher liver weight than the SD group, and the HCD + eugenol 10 mg group had a significantly lower liver weight than the HCD group.35
For adipose tissue weight, Jung et al. and Ding et al. showed that the epididymal adipose tissue weight in the HFD group with clove extract supplementation was significantly lower than the HFD group.33,34 Notably, White et al. showed that the epididymal and retroperitoneal adipose tissue weight were higher in the HFD group when compared to the SD group,31 demonstrating the effectiveness of the diets used.
As far as we know, no study has evaluated the relationship between the weight of brown adipose tissue, retroperitoneal adipose tissue, and the pancreas with eugenol clove oil supplementation. According to our results, eugenol supplementation did not improve the lipid profile. The HFDE group showed higher values of cholesterol and HDL, but the increase in HDL can be explained by the increase in total cholesterol. The literature shows opposing results for lipid profile.33,34 Elbahy; Madkour; Abdel-Raheem conducted a study in hyperlipidemic rats showing that the administration of 250 mg kg−1 of eugenol was beneficial for the lipid profile, with a significant reduction of total cholesterol and triglycerides in the hyperlipidemic group with eugenol when compared to the group without supplementation.37
It remains unclear why triglyceride levels were lower in the HFD group when compared to the SD group, but in the literature we found the same unexpected results with C57BL/6N mice.38
Harb et al. also confirmed the effect of eugenol as hypolipidemic, and the authors suggested that this effect is mediated in part by the potential transient vanilloid receptor 1 (TRPV1). TRPV1 is expressed in tissues, organs, and sensory nerves and is involved in functional regulation in the liver, pancreas, adipose tissue, and also blood vessels.39 The findings showed that TRPV1 expression is positively regulated in the liver of hypercholesterolemic rats; however, the precise molecular mechanism by which eugenol influences TRPV1 is unclear.35 But in fact, activation of TRPV1 signaling promotes accumulation of fat, while inhibiting this signaling protects against fat accumulation.40
Our study showed no difference in insulin levels among the experimental groups. Jung et al. found that insulin levels in the HFD group were higher than in HFD with clove extract supplement, suggesting that the increased levels were reduced with supplementation.33 Therefore, our findings do not agree with this previous result. Another study by Srinivasan et al., administered eugenol intragastrical in doses of 2.5 mg, 5 mg, and 10 mg kg−1 in diabetic Wistar rats for 30 days. The authors showed that 10 mg supplementation promoted a significant reduction in blood glucose levels, an increase in plasma insulin levels, and an improvement in body weight and hepatic glycogen content.41
Histological analysis demonstrated that eugenol had a possible protective effect on the liver, our findings confirm the results of Jung et al., Ding et al., Harb et al., and Jo et al., who found that eugenol or clove oil supplementation led to reduced fat droplets both in size and number.33–36 This effect might be explained by the role played by eugenol in decreasing the accumulation of hepatic lipid by modulating/activating calmodulin dependent protein kinase kinase (CAMKK) – AMP-activated protein kinase (AMPK) – sterol regulatory element-binding protein 1 (SREBP1) signaling pathway, as well as the regulation of lipolysis-related genes such as a cluster of differentiation 36 (CD36), carnitine palmitoyltransferase-1 (CPT-1) and acyl-CoA oxidase (ACO).36
Finally, regarding the gut microbiota profile, eugenol supplementation increased the abundance of the Firmicutes phylum in both HFD and SD groups. This phylum contains more than 250 genera, being considered the largest bacterial phylum. Some of their genera are Bacillus, Lactobacillus, Mollicutes, and Clostridium.42,43 Although Firmicutes are not considered beneficial due to their capacity to absorb calories from the diet and increase fat storage in the body,32 currently it is already known that within this phylum, some beneficial genera can be found such as Lactobacillus with immunomodulatory activity44 and Clostridium leptum with anti-inflammatory actions.45 Therefore, the exact bacterial species that make up this phylum must be better analyzed. In Bacteroidetes phylum, eugenol supplementation also increased the abundance of its groups. This phylum similarly to Firmicutes, can also have beneficial or harmful effects. Beneficially, it can play a role in the prevention of obesity and preventing colonization of the gastrointestinal tract by pathogenic agents, but on the other hand, it can also act as pathogenic and be involved in serious diseases and infections.46
In the third phylum analyzed, Actinobacteria, it was observed that supplementation also increased the abundance in the groups without eugenol, which does not agree with Ma et al., who found that the HFD and HFD with AEE groups decreased the abundance of Actinobacteria.32 This Gram-positive phylum, has a large diversity and many beneficial species with probiotic potential. It is divided into six classes: Actinobacteria, Acidimicrobiia, Coriobacteriia, Nitriliruptoria, Rubrobacteria, and Thermoleophilia,47,48 which together with the Proteobacteria represent only 10% of relative abundance in our gut microbiota. Although groups of Actinobacteria phylum represent a small percentage, they are essential in the development and maintenance of intestinal homeostasis. This phylum is supposed to be involved in the modulation of intestinal permeability, metabolism, immune system, and the gut–brain axis. In addition, some bacterial genera, especially Bifidoabcterium, play a modulating and therapeutic role in intestinal diseases such as irritable bowel syndrome, colorectal cancer, ulcerative colitis, among others, and also in extra-intestinal diseases, non-alcoholic liver steatosis, depression, respiratory pathologies, psoriasis, among others.49 Other beneficial effects of this phylum are being sources of new antibiotics, antifungals, and anticancer agents.47
The last analyzed phylum, Proteobacteria, was increased in the SDE group when compared to the SD group, and it was the only phylum whose abundance was reduced by eugenol supplementation in HFD even without a statistical difference. This may suggest a beneficial result since Proteobacteria has been recognized as producing metabolic endotoxemia (ME), that is, a change in permeability due to increased lipopolysaccharides (LPS).50 This ME drives the inflammatory process, triggers weight gain and can lead to diabetes onset.51 Besides, this phylum has also been associated with inflammation of the airways and the increase in its abundance causes an ecological imbalance, leading to greater severity of bronchiectasis.52
In addition to these harmful effects, according to some authors, Proteobacteria may represent a “microbial signature” of disease53 and also is considered as pathogenic with inflammatory potential, which may be the source of increased LPS levels in the visceral adipose tissue,54 and the proliferation of this phylum in the gut is associated with dysbiosis or reduced diversity of the intestinal microbial community.55
These Gram-negative bacteria, have the largest phylogenetic composition (116 bacterial families), and the phylum is divided into 6 classes: Alphaproteobacteria, Betaproteobacteria, Gammaproteobacteria, Deltaproteobacteria, Epsilonproteobacteria, and Zetaproteobacteria.53,55 To our knowledge, no further studies were found investigating eugenol and/or clove oil supplementation in mice fed with HFD. However, the antimicrobial activity of eugenol is already well established in the literature,24,25,56,57 although there are no studies that relate it to the gut microbiota of obese animals and/or humans. Therefore, more studies are required to elucidate the possible mechanisms involved in this outcome.
The limitations of the present study are related to the difficulty in finding studies with eugenol itself; therefore, those who administered clove extract were also used to discuss some variables. Another important limitation was regarding the dose administered. Despite being proved to be within a safe and non-toxic dosage, Harb et al. showed that eugenol in lower doses exhibited greater efficacy and better results in body and liver weight, and lipid profile using doses of eugenol at 10 mg and 100 mg associated with HFD in only 4 weeks of treatment.35
ACO | Acyl-CoA oxidase |
AEE | Aspirin ester with eugenol |
AMPK | AMP-activated protein kinase |
ANOVA | Analysis of variance |
AUC | Area under the curve |
CAMKK | Calmodulin dependent protein kinase kinase |
CD | Chronic disease |
CD36 | Cluster of differentiation 36 |
CPT-1 | Carnitine palmitoyltransferase-1 |
CT | Cycle threshold |
FC | Fold change |
FP | Forward primer |
GM | Gut microbiota |
GTT | Glucose tolerance test |
HCD | Hypercholesterolemic diet |
HFD | High-fat diet |
HFDE | High-fat diet with eugenol |
ME | Metabolic endotoxemia |
RP | Reverse primer |
SD | Standard diet |
SDE | Standard diet with eugenol |
SE | Standard error |
SREBP1 | Sterol regulatory element-binding protein 1 |
TRPV1 | Transient receptor potential cation channel subfamily V member 1 |
This journal is © The Royal Society of Chemistry 2022 |